News
Clinical Trials Arena on MSN3d
Neurocrine begins Phase III programme for schizophrenia treatmentThe primary goal of the trial is to measure the decrease in the Positive and Negative Syndrome Scale from baseline.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback